New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 3, 2014
18:56 EDTGSK, KKR, SNYPE firms mull combining older GSK, Sanofi drug brands, FT says
Private equity firms including KKR (KKR) and Warburg Pincus are considering purchasing the older drug portfolios of GlaxoSmithKline (GSK) and Sanofi (SNY) and combining them, says the Financial Times. Reference Link
News For GSK;SNY;KKR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
10:58 EDTKKRKKR to pay $30M to settle SEC charges of misallocating broken deal expenses
Subscribe for More Information
June 26, 2015
10:38 EDTGSKCourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
07:28 EDTKKRKKR-backed Coffee Day plans $181M IPO in India, Bloomberg reports
Coffee Day Enterprises, which includes KKR (KKR) among its investors, plans to raise as much as $181M from an initial share sale in India, Bloomberg reports. Kotak Mahindra Capital, Citi (C), and Morgan Stanley (MS) are among the managers to the planned sale, the report says. Reference Link
June 25, 2015
14:03 EDTSNYSanofi initiated with a Buy at HSBC
Subscribe for More Information
14:01 EDTGSKGlaxoSmithKline initiated with a Buy at HSBC
Price target GBP 17.
07:48 EDTKKRMorgan Stanley disregards Fed guidelines with $1B loan, NY Post reports
Subscribe for More Information
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
June 23, 2015
09:03 EDTKKR3M to buy Capital Safety from KKR in deal valued at $2.5B
3M (MMM) announced it has entered into a definitive agreement to acquire Capital Safety from KKR (KKR) for a total enterprise value of $2.5B, including the assumption of approximately $700M of debt, net of cash acquired. The business employs approximately 1,500 people worldwide and is headquartered in Bloomington, Minnesota. On a GAAP reported basis, 3M estimates the acquisition to be 4c dilutive to earnings in the first 12 months following completion of the transaction. Excluding purchase accounting adjustments and anticipated one-time expenses related to the transaction and integration, 3M estimates the acquisition to be 12c accretive to earnings over the same period. The transaction is expected to close in the third quarter, subject to customary closing conditions and regulatory approvals. 3M will finance the transaction with existing cash, a portion of which will come from outside the U.S.
08:45 EDTKKRKKR toa cquire C.H.I. Overhead Doors from FFL, terms not disclosed
Subscribe for More Information
07:25 EDTGSKPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:15 EDTKKRKKR announces strategic investment in Tarena
KKR (KKR) announced a strategic investment into Tarena International (TEDU), a provider of professional education services in China. In this transaction, KKR and Shaoyun Han, founder, Chairman and CEO of Tarena, had entered into definitive agreements to purchase an aggregate of $90.5M of ordinary shares in the company from existing pre-IPO shareholders, which are funds managed by affiliates of Goldman Sachs and IDG Technology Venture Investments, LLC. Pursuant to these agreements, KKR has agreed to purchase 6,826,263 Class A ordinary shares, representing an approximately 13% stake in the company, from the selling shareholders for a total purchase price of $70M. Han has agreed to purchase 2,000,000 Class A ordinary shares, representing an approximately 3.8% stake in the company, from the selling shareholders for a total purchase price of $20.5M, in private transactions. Han intends to fund the purchase through the issuance of a convertible bond to KKR, issued by an entity wholly owned by Han. The share purchase and sale transactions are expected to close in July, subject to customary closing conditions. KKR’s investment is through its China Growth Fund. Further details of the transaction are not disclosed.
08:06 EDTKKRTarena announces investment from KKR and Tarena CEO Shaoyun Han
Tarena (TEDU) announced that KKR (KKR) and Shaoyun Han, founder, chairman and CEO of Tarena, had entered into definitive agreements to purchase an aggregate of $90.5M of ordinary shares in the Company from existing pre-IPO shareholders, which are funds managed by affiliates of Goldman Sachs and IDG Technology Venture Investments, LLC. Pursuant to these agreements, KKR has agreed to purchase 6,826,263 Class A ordinary shares, representing an approximately 13% stake in the Company, from the selling shareholders for $70M, and Shaoyun Han has agreed to purchase 2,000,000 Class A ordinary shares, representing an approximately 3.8% stake in the company, from the selling shareholders for $20.5M, in private transactions. Mr. Han intends to fund the purchase through the issuance by an entity wholly owned by Han of a convertible bond to KKR.
08:02 EDTKKRTransphorm announces new $70M investment led by KKR
Subscribe for More Information
07:01 EDTGSKPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
June 18, 2015
13:08 EDTGSKGlaxoSmithKline management to meet with Piper Jaffray
Meeting to be held in Minneapolis on June 23 hosted by Piper Jaffray.
June 16, 2015
13:16 EDTGSKFDA appoves labeling changes for GSK anti-seizure drug
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use